CRISPR Therapeutics announces IPO

September 13, 2016

Share:

Pharmaceuticals | Basel, Switzerland | IPO

CRISPR Therapeutics, a gene-editing company developing therapeutics to alter specific sequences of DNA, plans to list shares on the NASDAQ under the symbol CRSP, according to an SEC filing. The company has raised venture funding from firms including Versant Ventures (20.7% pre-IPO stake) and New Enterprise Associates (9.7%). Bayer Global Investments has agreed to purchase $35 million worth of shares in the company at a yet-to-be-determined price.